Shares of Insmed Incorporated (INSM) plummeted 5.11% in pre-market trading on Thursday after the biopharmaceutical company reported a wider net loss for the fourth quarter of 2024 that missed analysts' expectations.
Insmed posted a net loss of $1.32 per diluted share for the quarter, wider than the loss of $1.28 per share in the year-ago period. Analysts polled by FactSet had forecast a loss of $1.17 per share.
While the company's revenue rose 24.8% year-over-year to $104.4 million, it narrowly missed the consensus estimate of $101.8 million. As of December 31, 2024, Insmed had cash, cash equivalents, and marketable securities totaling about $1.4 billion.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。